InMed Pharmaceuticals, Inc (IMLFF) Signs R&D Agreement with ATERA

0
451

InMed Signs R&D Agreement with ATERA

Under the terms of the agreement, ATERA will develop 3D human skin models of Epidermolysis Bullosa (‘EB’) to evaluate the in vitro drug efficacy of InMed’s lead compound, INM-750, a proprietary, topical cannabinoid product candidate targeted as a therapy in EB and other potential dermatological and wound-healing applications. ATERA will also investigate the beneficial effects of topically applied INM-750 at ultra-structural cellular and molecular levels on in vitro 3D reconstructed human full thickness (dermis-epidermis) skin models composed of both normal and EB-derived skin cells.

“INM-750 has demonstrated significant potential in pre-clinical models to address symptomatic improvement of EB including accelerated wound healing and a reduction in pain, itch and inflammation.  This project with ATERA is designed to assess the potential of INM-750 to have an impact in disease reversal, further supporting our current data indicating an up-regulation in specific keratins in the skin”, stated Dr. Sazzad Hossain , CSO of InMed. “By utilizing full-thickness skin models derived from EB skin samples, we can better validate INM-750’s target effect and efficacy in vitro ahead of our upcoming clinical trial program.”

“Producing 3D human tissue models of specific diseases in a controlled, reproducible fashion provides a unique tool for drug development screening”, says Bart De Wever , CEO of ATERA. “Our core technology enables the development of 3D human skin models engineered of cells from EB patient biopsies that will help InMed investigate the mode-of-action of its lead compound INM-750.”

About ATERA
ATERA SAS ( Villeneuve Loubet , France ) is a tissue-engineering company specialized in the development, validation, manufacturing and commercialization of advanced human tissue models as reliable, cost-effective, high-quality and more conscientious alternatives for animal experimentation in product evaluation, industrial safety and efficacy as well as medical research. For more information, visit http://www.ateralabs.com

About InMed
InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, clinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed’s proprietary bioinformatics database assessment tool, the biosynthesis manufacturing process and its drug development programs are the fundamental value drivers of the Company.

For more information, visit www.inmedpharma.com.

Cautionary Note Regarding Forward-Looking Information

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws.  Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.  Forward-looking information in this news release includes statements about:the final formulation for INM-750 being used for IND-enabling pharmacology and toxicology studies and subsequent clinical trials and the expected fundamental value drivers of the Company.

LEAVE A REPLY

Please enter your name here
Please enter your comment!